26,620 Shares in Guardant Health, Inc. $GH Bought by Revere Asset Management Inc

Revere Asset Management Inc purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 26,620 shares of the company’s stock, valued at approximately $3,994,000. Guardant Health comprises approximately 1.5% of Revere Asset Management Inc’s portfolio, making the stock its 11th largest holding.

Several other large investors also recently bought and sold shares of the stock. ABS Investment Management LLC purchased a new position in shares of Guardant Health during the second quarter worth about $345,069,000. MCF Advisors LLC increased its position in shares of Guardant Health by 755.0% during the second quarter. MCF Advisors LLC now owns 171 shares of the company’s stock worth $26,000 after purchasing an additional 151 shares in the last quarter. TrinityBridge Ltd purchased a new stake in shares of Guardant Health in the 2nd quarter valued at about $45,000. Elyxium Wealth LLC purchased a new stake in shares of Guardant Health in the 4th quarter valued at about $35,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of Guardant Health in the 2nd quarter valued at about $59,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insiders Place Their Bets

In other Guardant Health news, Director Ian T. Clark sold 14,180 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total value of $2,253,485.60. Following the transaction, the director directly owned 2,975 shares of the company’s stock, valued at approximately $472,787. The trade was a 82.66% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Musa Tariq sold 1,951 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $255,893.16. Following the transaction, the director owned 11,048 shares of the company’s stock, valued at approximately $1,449,055.68. The trade was a 15.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 427,024 shares of company stock valued at $67,113,285. 5.60% of the stock is owned by company insiders.

Guardant Health Trading Up 6.6%

Shares of NASDAQ GH traded up $10.46 during midday trading on Monday, reaching $167.84. 1,493,089 shares of the company were exchanged, compared to its average volume of 2,255,241. The stock has a market cap of $22.52 billion, a P/E ratio of -48.09 and a beta of 1.57. Guardant Health, Inc. has a 1 year low of $53.40 and a 1 year high of $176.58. The stock has a fifty day simple moving average of $159.72 and a 200 day simple moving average of $124.86.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.34. The company had revenue of $334.98 million for the quarter, compared to analysts’ expectations of $314.23 million. During the same period in the prior year, the company earned ($0.44) earnings per share. The firm’s revenue was up 44.3% on a year-over-year basis. As a group, analysts forecast that Guardant Health, Inc. will post -2.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Bank of America raised their price target on Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. Canaccord Genuity Group boosted their price objective on Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Evercore reissued an “outperform” rating and issued a $200.00 price objective on shares of Guardant Health in a report on Monday, July 6th. Morgan Stanley raised their target price on shares of Guardant Health from $175.00 to $185.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Finally, Mizuho raised their target price on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $188.12.

Guardant Health Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.